XTalks

DECEMBER 2, 2024

The US Food and Drug Administration (FDA) has approved AOP Health’s landiolol injection, marketed as Rapiblyk, for the treatment of atrial fibrillation (Afib) and atrial flutter in critical care settings. This approval marks Rapiblyk’s introduction to the US market after being available in Europe.

Trials 104

Trials Marketing FDA Approval Life Science 104

Pharma Marketing Network

FEBRUARY 19, 2025

Introduction Email marketing remains one of the most powerful tools for pharma brands , helping reach healthcare professionals (HCPs), patients, and stakeholders with tailored messaging. But email marketing campaigns in the pharmaceutical industry come with unique challenges regulatory restrictions, privacy concerns, and engagement barriers.

Compliance 72

Compliance Marketing Branding Regulation 72

XTalks

NOVEMBER 26, 2024

A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025. The availability of a treatment that addresses both survival and quality of life represents a long-awaited milestone for patients and their caregivers.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

The Pharma Data

NOVEMBER 2, 2020

FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis. Food and Drug Administration (FDA) approval of Bronchitol (mannitol) inhalation powder. Food and Drug Administration (FDA) approval of Bronchitol (mannitol) inhalation powder.

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

pharmaphorum

JUNE 22, 2021

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. .

Sales 98

Sales Marketing FDA Approval Trials 98

Delveinsight

AUGUST 3, 2021

Nevro Received FDA Approval of its 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy. received approval for its Senza System, Nevro’s unique 10 kHz stimulation, to treat chronic pain associated with Painful Diabetic Neuropathy (PDN).

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

The Pharma Data

JULY 12, 2021

“With our longstanding expertise in innovative science in the cardiovascular space, today’s approval of finerenone marks an important milestone in Bayer’s commitment to improving the lives of patients with kidney and cardiovascular diseases.”. FDA has approved finerenone for marketing authorization in the U.S.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

XTalks

JULY 19, 2021

Phosphorus may be a familiar name as it was one of the first to develop an FDA-authorized at-home test for COVID-19 ; it was also the first test to have received an asymptomatic, direct-to-consumer FDA approval.

Genetics 98

Genetics Genome Genomics Gene 98

XTalks

FEBRUARY 9, 2024

As we delve into the top 15 cardiovascular disease drugs in 2023, guided by comprehensive 2022 sales data, we gain valuable insights into the market trends, drug efficacy and the evolving needs of patients worldwide. Eliquis’ growing success in recent years owes largely to gains in the non-valvular atrial fibrillation market.

Sales 59

Sales FDA Approval Drugs Marketing 59

pharmaphorum

JANUARY 12, 2021

Lilly and Boehringer claim almost 60% market share for Jardiance among SGLT2 drugs used to treat type 2 diabetes, driving blockbuster sales for the brand. Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.

Sales 76

Sales FDA Approval Trials Marketing 76

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga. Sales have rocketed ever since, climbing 30% to almost $2 billion last year, and 60% to $1.36

Cardiology 52

Cardiology Sales Marketing FDA Approval 52

XTalks

FEBRUARY 8, 2024

Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDA approval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

pharmaphorum

JULY 7, 2021

The top-line data sets up a possible market clash with Novartis, which secured the first FDA approval for a drug treatment for HFpEF in February, although the label for its Entresto (sacubitril/valsartan) drug says that its benefits are more evident in patients with reduced ejection fraction.

Sales 52

Sales Cardiology FDA Approval Trials 52

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed. The market access lever is more heavily applied in Europe than the US.

Sales 105

Sales Marketing Production Vaccination 105

Delveinsight

AUGUST 4, 2020

MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies. Billion deal in a thirst to grow in the cancer market. Siemens Healthineers, formed as a result of spin-off in 2018, plans to increase its presence in oncology, neurology as well as cardiology domain.

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

XTalks

JUNE 11, 2024

Market Dynamics: Understanding Agent DCB’s Competitors Boston Scientific’s Agent DCB operates in an extremely competitive market. This hybrid approach demonstrates the versatility and potential overlap in technology between DES and DCB markets.

Drugs 52

Drugs Drug Delivery Cardiology Marketing 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. The FDA approved the drug over a decade ago in September 2009.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 25, 2020

Abiomed has a long-established track record of bringing to market improved options to support physicians with innovative technology like Breethe, which is designed to provide advanced respiratory and cardiac support,” said Bartley Griffith, MD, the Hales Distinguished Professor of Surgery at University of Maryland, School of Medicine.

Cardiology 52

Cardiology FDA Approval Development Engineer 52

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

NOVEMBER 4, 2020

Amarin’s decision to continue to invest in expanding the market for VASCEPA also reflects its confidence in its manufacturing processes, which the company has built over a decade to achieve consistent, high-quality, stable supply to support anticipated global demand. commercial team.

Sales 40

Sales Production Marketing Cardiology 40

The Pharma Data

APRIL 26, 2021

(USD 789 million, +34% cc) sustained strong growth with increased patient share across markets, driven by demand as the essential first choice therapy for heart failure patients. USD 319 million, +81% cc) had a strong quarter with growth driven by Europe and Emerging Growth Markets, as well as ongoing geographic expansion. Entresto.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

OCTOBER 29, 2020

approval & positive CHMP opinion for ULTOMIRIS 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & aHUS. Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS ® (eculizumab) in 3 largest markets – U.S. Received U.S.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

XTalks

NOVEMBER 7, 2024

Johnson & Johnson (J&J) MedTech recently received US Food and Drug Administration (FDA) approval for its VARIPULSE pulsed field ablation (PFA) platform, making it the first PFA system in the US to be fully integrated with the CARTO 3 electro-anatomical mapping system for treating paroxysmal atrial fibrillation (AFib).

Marketing 105

Marketing FDA Approval Clinical Trials Clinical Trials 105

XTalks

DECEMBER 19, 2024

The US Food and Drug Administration (FDA) has rejected Johnson & Johnsons (J&J) application for a subcutaneous formulation of Rybrevant (amivantamab). In August, the FDA approved Janssen Biotechs EGFR kinase inhibitor Lazcluze in combination with Rybrevant as a first-line treatment for NSCLC with EGFR exon 20 insertion mutations.

Sales 97

Sales FDA Approval Licensing Licensing 97

XTalks

OCTOBER 25, 2024

Related: Surmodics and Abbott’s Drug-Coated Balloon for Peripheral Artery Disease Gets FDA Approval Heart failure affects about 6.5 Abbott’s HeartMate 3 is currently the leader in the cardiovascular medical device market. According to GlobalData, the market is expected to reach a value of $86.5 billion by 2033.

Trials 105

Trials Manufacturing FDA Approval Marketing 105